Table II.
Overview of the biomarkers of triple-negative breast cancer.
| Characteristics | Patients, n (%) |
|---|---|
| Ki-67 expression, % | |
| 0 | 11 (7.6) |
| 1–10 | 39 (26.9) |
| 11–50 | 36 (24.8) |
| 51–100 | 59 (40.7) |
| p53 | |
| Negative | 91 (62.8) |
| Positive | 54 (37.2) |
| Androgen receptor | |
| Negative | 128 (88.3) |
| Positive | 17 (11.7) |
| Vimentin | |
| Negative | 81 (55.9) |
| Positive | 64 (44.1) |
| Breast cancer susceptibility gene 1 | |
| Negative | 110 (75.9) |
| Positive | 35 (24.1) |
| EGFR | |
| Negative | 123 (84.8) |
| Positive | 22 (15.2) |
| CK5/6 | |
| Negative | 99 (68.3) |
| Positive | 46 (31.7) |
| Basal-like | |
| EGFR and CK5/6 negative | 88 (60.7) |
| EGFR or CK5/6 positive | 57 (39.3) |
| Aldehyde dehydrogenase 1 | |
| Grade 0 | 45 (31.0) |
| Grade 1+ | 20 (13.8) |
| Grade 2+ | 28 (19.3) |
| Grade 3+ | 52 (35.9) |
EGFR, epidermal growth factor receptor; CK5/6, cytokeratin 5/6.